Cansino OTC Stock Today


USD 5.45  0.06  1.09%   

Market Performance
0 of 100
Odds Of Distress
Over 73
Cansino Biologics is trading at 5.45 as of the 28th of September 2022, a -1.09% down since the beginning of the trading day. The stock's lowest day price was 5.45. Cansino Biologics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cansino Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of October 2020 and ending today, the 28th of September 2022. Click here to learn more.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. The company has 132.67 M outstanding shares. More on Cansino Biologics

Moving together with Cansino Biologics

+0.66HPQHp Inc Fiscal Year End 22nd of November 2022 PairCorr

Moving against Cansino Biologics

-0.55DISWalt Disney Fiscal Year End 9th of November 2022 PairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Cansino Biologics OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cansino Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cansino Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Cansino Biologics generated a negative expected return over the last 90 days
Cansino Biologics has high historical volatility and very poor performance
Cansino Biologics has high likelihood to experience some financial distress in the next 2 years
About 27.0% of the company shares are held by company insiders
On 31st of August 2022 Cansino Biologics paid $ 0.1194 per share dividend to its current shareholders
Latest headline from WHO chief reiterates belief that COVID-19 pandemic end near, says work still needed - Seeking Alpha
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Cansino Biologics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellFairly Valued
Cansino Biologics [CASBF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.85 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cansino Biologics's market, we take the total number of its shares issued and multiply it by Cansino Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Cansino Biologics classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 132.67 M outstanding shares. Cansino Biologics has accumulated about 7.12 B in cash with 1.46 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 28.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cansino Biologics Probability Of Bankruptcy
Cansino Biologics holds a total of one hundred thirty-two million six hundred sixty-nine thousand nine hundred ninety-nine outstanding shares. Cansino Biologics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Cansino Ownership Details

Cansino Stock Price Odds Analysis

What are Cansino Biologics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Cansino Biologics jumping above the current price in 90 days from now is about 98.0%. The Cansino Biologics probability density function shows the probability of Cansino Biologics otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Cansino Biologics has a beta of 0.2475 suggesting as returns on the market go up, Cansino Biologics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cansino Biologics will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Cansino Biologics is significantly underperforming DOW.
  Odds Below 5.45HorizonTargetOdds Above 5.45
1.90%90 days
Based on a normal probability distribution, the odds of Cansino Biologics to move above the current price in 90 days from now is about 98.0 (This Cansino Biologics probability density function shows the probability of Cansino OTC Stock to fall within a particular range of prices over 90 days) .

Cansino Biologics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cansino Biologics market risk premium is the additional return an investor will receive from holding Cansino Biologics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cansino Biologics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cansino Biologics' alpha and beta are two of the key measurements used to evaluate Cansino Biologics' performance over the market, the standard measures of volatility play an important role as well.

Cansino Stock Against Markets

Picking the right benchmark for Cansino Biologics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cansino Biologics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cansino Biologics is critical whether you are bullish or bearish towards Cansino Biologics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cansino Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now


Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Invested in Cansino Biologics?

The danger of trading Cansino Biologics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cansino Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cansino Biologics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cansino Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Cansino Biologics information on this page should be used as a complementary analysis to other Cansino Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Cansino OTC Stock analysis

When running Cansino Biologics price analysis, check to measure Cansino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansino Biologics is operating at the current time. Most of Cansino Biologics' value examination focuses on studying past and present price action to predict the probability of Cansino Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cansino Biologics' price. Additionally, you may evaluate how the addition of Cansino Biologics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Cansino Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cansino Biologics. If investors know Cansino will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cansino Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cansino Biologics is measured differently than its book value, which is the value of Cansino that is recorded on the company's balance sheet. Investors also form their own opinion of Cansino Biologics' value that differs from its market value or its book value, called intrinsic value, which is Cansino Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cansino Biologics' market value can be influenced by many factors that don't directly affect Cansino Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cansino Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cansino Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cansino Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.